Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $256.75M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.47M
Average 7.51M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +21.0% | +203.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.0% over three years. Forward estimates point to Revenue at +203.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Omeros Corporation NASDAQ:OMER | $1.27B | $17.49 | Not rated | 8.4 | +63.76% |
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | $796.97M | $1.79 | Not rated | -30.5 | +21.09% |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -24.49% |
Neurogene Inc. NASDAQ:NGNE | $378.15M | $23.93 | Not rated | -7.1 | +8.15% |
Fulcrum Therapeutics, Inc. NASDAQ:FULC | $287.64M | $3.77 | Not rated | -3.6 | -61.46% |
Lineage Cell Therapeutics, Inc. AMEX:LCTX | $231.31M | $0.91 | Not rated | -4.6 | -53.91% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | $1.34 | Not rated | -1.2 | -66.25% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | $0.77 | Not rated | -5.5 | -87.69% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.